Clinical Trial Update: Vaccine Treatment for Hormone Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial update for a vaccine treatment targeting hormone-refractory prostate cancer has completed enrollment and/or data collection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Vaccine Treatment (unspecified)

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED